Literature DB >> 18220653

Role of endogenous androgen against insulin resistance and athero- sclerosis in men with type 2 diabetes.

Michiaki Fukui1, Yoshihiro Kitagawa, Hiroyuki Ose, Goji Hasegawa, Toshikazu Yoshikawa, Naoto Nakamura.   

Abstract

Age-related decline in serum testosterone and dehydroepiandrosterone sulfate concentrations occur in men. Low concentrations of these endogenous androgens have been linked with insulin resistance, which is an important upstream driver for metabolic abnormalities such as hyperglycemia, hypertension, or hyperlipidemia, and increased cardiovascular risk. Moreover, men with diabetes have significantly less circulating androgen than nondiabetic men. Here, we summarize how androgen affects insulin resistance and atherosclerosis in men with type 2 diabetes. Low serum concentrations of endogenous androgens are associated with visceral fat accumulation. Androgen deprivation by castration to treat prostate cancer increases insulin resistance, while testosterone administration in type 2 diabetic men with androgen deficiency improves glucose homeostasis and decreases visceral fat, in addition to alleviating symptoms of androgen deficiency including erectile dysfunction. Androgen correlates inversely with severity of atherosclerosis and has beneficial effects upon vascular reactivity, inflammatory cytokine, adhesion molecules, insulin resistance, serum lipids, and hemostatic factors. Because men with type 2 diabetes have relative hypogonadism, testosterone supplementation could decrease both insulin resistance and atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18220653     DOI: 10.2174/157339907779802094

Source DB:  PubMed          Journal:  Curr Diabetes Rev        ISSN: 1573-3998


  9 in total

1.  Susceptibility to diet-induced hepatic steatosis and glucocorticoid resistance in FK506-binding protein 52-deficient mice.

Authors:  Manya Warrier; Terry D Hinds; Kelly J Ledford; Harrison A Cash; Payal R Patel; Thomas A Bowman; Lance A Stechschulte; Weidong Yong; Weinian Shou; Sonia M Najjar; Edwin R Sanchez
Journal:  Endocrinology       Date:  2010-04-28       Impact factor: 4.736

2.  Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome.

Authors:  A Aversa; R Bruzziches; D Francomano; G Spera; A Lenzi
Journal:  J Endocrinol Invest       Date:  2010-03-10       Impact factor: 4.256

3.  Dihydrotestosterone modulates endothelial progenitor cell function via RhoA/ROCK pathway.

Authors:  Hao Zhang; Liang Shi; Guo-Qing Ren; Wen-Wen Sun; Yi-Bin Wang; Yi-Kun Chen; Jiang-Ning Yin; Bing Wan
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

4.  Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine?

Authors:  Antonio Aversa; Roberto Bruzziches; Davide Francomano; Marco Natali; Andrea Lenzi
Journal:  Ther Adv Urol       Date:  2009-10

5.  Dual targeting of the antagonistic pathways mediated by Sirt1 and TXNIP as a putative approach to enhance the efficacy of anti-aging interventions.

Authors:  Shaker A Mousa; Christine Gallati; Tessa Simone; Emmy Dier; Murat Yalcin; Evgeny Dyskin; Sudha Thangirala; Christine Hanko; Abdelhadi Rebbaa
Journal:  Aging (Albany NY)       Date:  2009-03-31       Impact factor: 5.682

6.  Long-term Safety of Testosterone and Growth Hormone Supplementation: A Retrospective Study of Metabolic, Cardiovascular, and Oncologic Outcomes.

Authors:  Enrique Ginzburg; Nancy Klimas; Chad Parvus; Jeff Life; Robert Willix; Michale J Barber; Alvin Lin; Florence Comite
Journal:  J Clin Med Res       Date:  2010-08-18

7.  Effects of androgens on endothelial progenitor cells in vitro and in vivo.

Authors:  Gian Paolo Fadini; Mattia Albiero; Andrea Cignarella; Chiara Bolego; Christian Pinna; Elisa Boscaro; Elisa Pagnin; Renzo De Toni; Saula de Kreutzenberg; Carlo Agostini; Angelo Avogaro
Journal:  Clin Sci (Lond)       Date:  2009-09-07       Impact factor: 6.124

8.  Let-7e-5p Regulates IGF2BP2, and Induces Muscle Atrophy.

Authors:  Takuro Okamura; Hiroshi Okada; Yoshitaka Hashimoto; Saori Majima; Takafumi Senmaru; Naoko Nakanishi; Mai Asano; Masahiro Yamazaki; Masahide Hamaguchi; Michiaki Fukui
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-24       Impact factor: 5.555

9.  Impact of Metabolic Syndrome Factors on Testosterone and SHBG in Type 2 Diabetes Mellitus and Metabolic Syndrome.

Authors:  Mukhtar Mohammed; Molham Al-Habori; Ahmed Abdullateef; Riyadh Saif-Ali
Journal:  J Diabetes Res       Date:  2018-07-02       Impact factor: 4.011

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.